MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification

MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification

Ça&gbreve;lar Ünal,1 Tolga Özmen,2,3 Ahmet Serkan &Idot;lgün,4 Çetin Ordu,5 Enver Özkurt,6 Naziye Ak,7 Gül Alço,8 Zeynep Erdo&gbreve;an &Idot;yigün,9 Sevgi Kurt,10 Tomris Duymaz,11 Mehmet Alper Öztürk,12 Filiz Elbüken Çelebi,13 Kanay Yararba&scedil;,14 Gürsel Soybir,15 Fatma Akte...

Full description

Bibliographic Details
Main Authors:	Ünal Ç, Özmen T, İlgün AS, Ordu Ç, Özkurt E, Ak N, Alço G, Erdoğan İyigün Z, Kurt S, Duymaz T, Öztürk MA, Elbüken Çelebi F, Yararbaş K, Soybir G, Aktepe F, Özmen V
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-09-01
Series:	Breast Cancer: Targets and Therapy
Subjects:	breast cancer mcm-2 oncotype dx recurrence score tailorx risk categorization
Online Access:	https://www.dovepress.com/mcm-2-levels-as-a-potential-biomarker-for-predicting-high-risk-breast--peer-reviewed-fulltext-article-BCTT

Similar Items

Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization
by: Çağlar Ünal, et al.
Published: (2023-10-01)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
by: Çağlar Ünal, et al.
Published: (2023-06-01)

Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey
by: Vahit Özmen, et al.
Published: (2016-07-01)

New Approaches in Breast Cancer Radiotherapy
by: Niyazi Volkan Demircan, et al.
Published: (2024-01-01)

The evolution of gene expression profiling in breast cancer – A narrative review
by: Banushree Chandrasekhar Srinivasamurthy
Published: (2023-01-01)

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
by: Thomas M. Schwedhelm, et al.
Published: (2020-09-01)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
by: Xiaofu Zhu, et al.
Published: (2021-02-01)

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
by: Evelien Schaafsma, et al.
Published: (2021-07-01)

Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
by: T. M. Aherne, et al.
Published: (2020-04-01)

Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle- Income Country, Turkey: Results of a Prospective Multicenter Study
by: Vahit Özmen, et al.
Published: (2019-07-01)

The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer
by: Yael Bar, et al.
Published: (2024-10-01)

The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
by: Stephane Thibodeau, et al.
Published: (2019-07-01)

Spotlight on the utility of the Oncotype DX® breast cancer assay
by: Siow ZR, et al.
Published: (2018-02-01)

The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes
by: Jun Wang, et al.
Published: (2018-12-01)

Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis
by: Ping Zhou, et al.
Published: (2020-12-01)

Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling
by: S Aggarwal, et al.
Published: (2018-01-01)

The Effect of Systemic Chemotherapy on Ovarian Function: A Prospective Clinical Trial
by: Filiz Çelebi, et al.
Published: (2020-07-01)

Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array
by: Hans-Ullrich Völker, et al.
Published: (2018-08-01)

Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany
by: M.P. Lux, et al.
Published: (2022-01-01)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective
by: Berdunov V, et al.
Published: (2024-06-01)

The Effect of Mini-Latissimus Dorsi Flap (MLDF) Reconstruction on Shoulder Function in Breast Cancer Patients
by: Tomris Duymaz, et al.
Published: (2019-07-01)

Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
by: Dániel Deme, et al.
Published: (2024-04-01)

Corrigendum: Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
by: Dániel Deme, et al.
Published: (2024-07-01)

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline
by: Phillip Blanchette, et al.
Published: (2022-04-01)

Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes
by: Suk Jun Lee, et al.
Published: (2023-11-01)

NURR1 Is Differentially Expressed in Breast Cancer According to Patient Racial Identity and Tumor Subtype
by: Shahensha Shaik, et al.
Published: (2022-12-01)

A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX ® testing to guide adjuvant chemotherapy decisions
by: Asma Munir, et al.
Published: (2023-01-01)

Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up
by: Cihan Uras, et al.
Published: (2022-11-01)

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer
by: Yogeshkumar Malam, et al.
Published: (2022-08-01)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers
by: Pascale A. Cohen, et al.
Published: (2019-05-01)

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
by: McVeigh TP, et al.
Published: (2017-05-01)

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center
by: John Loggie, et al.
Published: (2024-06-01)

Evaluation of Long-Term Lymphedema Rate in Patients With Subclinical Lymphedema Diagnosed in the Preoperative Period via Bioimpedance
by: Zeynep Erdoğan İyigün, et al.
Published: (2025-01-01)

Outcomes of reconstructive techniques in breast cancer using BCCT. core software
by: Sevgi Kurt, et al.
Published: (2024-03-01)

The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx
by: Michał Jarząb, et al.
Published: (2024-10-01)

The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer
by: Atilla Soran, et al.
Published: (2020-04-01)

Correlation analysis between mammography features of early-stage invasive breast ductal carcinoma with positive ER, negative HER2, negative lymph node and Oncotype DX21 gene assay results
by: WANG Ting , LIU Zhuang , GONG Jing , JIANG Lin , SHEN Xigang , GU Yajia
Published: (2021-06-01)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
by: Michael Crager, et al.
Published: (2022-11-01)

Corrigendum: Genomic Assays in Node Positive Breast Cancer Patients: A Review
by: Maroun Bou Zerdan, et al.
Published: (2021-04-01)

Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: A Comparative Analysis of Treatment Administration before and after TAILORx
by: Elena Diana Chiru, et al.
Published: (2023-12-01)